

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: TMI218693

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
COHERUS BIOSCIENCES, INC.		05/08/2024	Corporation: DELAWARE
COHERUS INTERMEDIATE CORP.		05/08/2024	Corporation: DELAWARE
INTEKRIN THERAPEUTICS INC.		05/08/2024	Corporation: DELAWARE
SURFACE ONCOLOGY, LLC	FORMERLY SURFACE ONCOLOGY, INC.	05/08/2024	Limited Liability Company: DELAWARE
COHERUS ONCOLOGY SUPPORTIVE CARE LLC		05/08/2024	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Company Name:</b>	ANKURA TRUST COMPANY, LLC		
<b>Street Address:</b>	140 Sherman Street, 4th Floor		
<b>City:</b>	Fairfield		
<b>State/Country:</b>	CONNECTICUT		
<b>Postal Code:</b>	06824		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 14</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	7243078	YUSIMRY	
<b>Registration Number:</b>	5710007	UDENYCA	
<b>Registration Number:</b>	7327960	LOQTORZI	
<b>Registration Number:</b>	6921362	COHERUS	
<b>Registration Number:</b>	6147626		
<b>Registration Number:</b>	6921363	COHERUS BIOSCIENCES	
<b>Registration Number:</b>	7183187	SURFACE ONCOLOGY	
<b>Registration Number:</b>	5710905		
<b>Registration Number:</b>	7183207	SURFACE ONCOLOGY	
<b>Registration Number:</b>	5874928	SURFACE ONCOLOGY	
<b>Registration Number:</b>	6094924	SURFACE ONCOLOGY	
<b>Registration Number:</b>	6094923	SURFACE ONCOLOGY	

OP \$365.00.00 90169471

Property Type	Number	Word Mark
Serial Number:	98344332	COHERUS
Serial Number:	98344323	

**CORRESPONDENCE DATA**

**Fax Number:** 7043485200  
*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*  
**Phone:** 7043487844  
**Email:** Moira.Sheehan@cwt.com  
**Correspondent Name:** Moira Sheehan  
**Address Line 1:** 650 South Tryon Street  
**Address Line 2:** Suite 1400  
**Address Line 4:** Charlotte, NORTH CAROLINA 28202

<b>ATTORNEY DOCKET NUMBER:</b>	17933.001
<b>NAME OF SUBMITTER:</b>	Moira Sheehan
<b>SIGNATURE:</b>	Moira Sheehan
<b>DATE SIGNED:</b>	05/08/2024

**Total Attachments: 10**  
source=Barings - Coherus - IP Security Agreement (2024) [Execution Version]#page1.tif  
source=Barings - Coherus - IP Security Agreement (2024) [Execution Version]#page2.tif  
source=Barings - Coherus - IP Security Agreement (2024) [Execution Version]#page3.tif  
source=Barings - Coherus - IP Security Agreement (2024) [Execution Version]#page4.tif  
source=Barings - Coherus - IP Security Agreement (2024) [Execution Version]#page5.tif  
source=Barings - Coherus - IP Security Agreement (2024) [Execution Version]#page6.tif  
source=Barings - Coherus - IP Security Agreement (2024) [Execution Version]#page7.tif  
source=Barings - Coherus - IP Security Agreement (2024) [Execution Version]#page8.tif  
source=Barings - Coherus - IP Security Agreement (2024) [Execution Version]#page9.tif  
source=Barings - Coherus - IP Security Agreement (2024) [Execution Version]#page10.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of May 8, 2024, is made by COHERUS BIOSCIENCES, INC., a Delaware Corporation ("Borrower"), COHERUS INTERMEDIATE CORP., a Delaware corporation ("Coherus Intermediate"), INTEKRIN THERAPEUTICS INC., a Delaware corporation ("Intekrin"), SURFACE ONCOLOGY, LLC, a Delaware limited liability company ("Surface Oncology"), COHERUS ONCOLOGY SUPPORTIVE CARE LLC, a Delaware limited liability company ("Coherus Oncology"), together with Borrower, Coherus Intermediate, Intekrin and Surface Oncology, individually and collectively, "Grantor", in favor of ANKURA TRUST COMPANY, LLC (together with its successors and permitted assigns, the "Collateral Agent") on behalf of Lenders and the other Secured Parties (as defined in the Loan Agreement referred to below).

WITNESSETH:

WHEREAS, pursuant to the Loan Agreement, dated as of May 8, 2024 (as the same may be amended, amended and restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), by and among Borrower, Coherus Intermediate, Intekrin, Surface Oncology, Coherus Oncology, the Collateral Agent, and each of the lenders signatory thereto (each a "Lender" and collectively, the "Lenders"), each Lender has agreed to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, Grantor (other than Borrower) has agreed, pursuant to a Guaranty and Security Agreement, dated as of May 8, 2024, in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties (as such agreement may be amended, amended and restated, supplemented or otherwise modified from time to time, the "Guaranty and Security Agreement"), to guarantee the Obligations (as defined in the Loan Agreement) of Borrower; and

WHEREAS, Grantor is party to the Guaranty and Security Agreement pursuant to which Grantor is required to execute and deliver this Intellectual Property Security Agreement;

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree, intending to be legally bound, as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. Grant of Security Interest in Intellectual Property Collateral. Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, hereby mortgages, pledges and hypothecates to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, and grants to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of Grantor, in each case, solely to the extent constituting Collateral (and excluding any Excluded Property) (the "Intellectual Property Collateral"):

(a) any and all United States Patents, Trademarks, Copyrights and other Intellectual Property and IP Licenses (including Current Company IP Agreements to which a Grantor is a party and the rights of such Grantor thereunder, and all of a Grantor's right, title and interest in, to and under any Internet Domain Names and Software) owned by a Grantor which, in each case, relates in any way to any research, development, testing, approval, post-approval monitoring, reporting, manufacture, production, packaging, labelling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale or lease, distribution, or sale or lease of Product in the Territory, including, without limitation, those described in Schedule 1 hereto, and all renewals, reversions, extensions, reissues, reexaminations, continuations, continuations-in-part, divisionals, substitutes, adjustments, confirmations and registrations of the foregoing, as applicable; and

(b) all proceeds, products, accessions, rents and profits of or in respect of any of the foregoing.

Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Intellectual Property Security Agreement is granted in conjunction with the security interest granted to the Collateral Agent for the benefit of Lenders and the other Secured Parties, pursuant to the Guaranty and Security Agreement and Grantor hereby acknowledges and agrees that the obligations, rights and remedies of Grantor and of the Collateral Agent on behalf of Lenders and the other Secured Parties with respect to the security interest in the Intellectual Property Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other reasonably necessary actions in connection with their Intellectual Property and IP Licenses subject to a security interest hereunder.

Section 5. Counterparts. This Intellectual Property Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page of this Intellectual Property Security Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.


Section 6. Governing Law. THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

IN WITNESS WHEREOF, Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,


COHERUS BIOSCIENCES, INC.,

as a ~~Grantor~~ Signed by:

By:   
Name: Dennis M. Lanfear  
Title: Chief Executive Officer

COHERUS INTERMEDIATE CORP.,

as a ~~Grantor~~ Signed by:

By:   
Name: Dennis M. Lanfear  
Title: President and Chief Executive Officer


INTEKRIN THERAPEUTICS INC.,

as a ~~Grantor~~ Signed by:

By:   
Name: Dennis M. Lanfear  
Title: Chief Financial Officer and Treasurer


SURFACE ONCOLOGY, LLC,

as a ~~Grantor~~ Signed by:

By:   
Name: Dennis M. Lanfear  
Title: President

COHERUS ONCOLOGY SUPPORTIVE CARE LLC,

as a ~~Grantor~~ Signed by:

By:   
Name: Dennis M. Lanfear  
Title: President

ACCEPTED AND AGREED  
as of the date first above written:

ANKURA TRUST COMPANY, LLC,  
as Collateral Agent

By *Beth Micena*  
Name: Beth Micena  
Title: Managing Director

SCHEDULE I  
TO  
INTELLECTUAL PROPERTY SECURITY AGREEMENT

Intellectual Property

*1. Patents:*

Title	Assignee	App. No.	Filing Date	Applicant Name	Patent No.
<b>Etanercept Formulations Stabilized with Metal Ions</b>	Coherus Biosciences, Inc.	13/654770	10/18/2012	Coherus Biosciences, Inc.	9801942
<b>Etanercept Formulations Stabilized with Xylitol</b>	Coherus Biosciences, Inc.	13/654919	10/18/2012	Coherus Biosciences, Inc.	9393305
<b>Solid pharmaceutical compositions of ppar<math>\gamma</math> modulator</b>	Intekrin Therapeutics Inc.	13/824776	9/19/2011	Lee; Kathleen M. Higgins; Linda Lanfear; Dennis	9675603
<b>PPAR gamma agonists for treatment of multiple sclerosis</b>	Intekrin Therapeutics Inc.	14/162723	1/23/2014	Intekrin Therapeutics Inc.	9061020
<b>Perfusion method for manufacturing etanercept</b>	Coherus Biosciences, Inc.	14/226522	3/26/2014	Coherus Biosciences, Inc.	9765139
<b>Etanercept formulations exhibiting marked reduction in sub-visible particles</b>	Coherus Biosciences, Inc.	14/592569	1/8/2015	Coherus Biosciences, Inc.	10822429
<b>Stable aqueous formulations of etanercept</b>	Coherus Biosciences, Inc.	14/592654	1/8/2015	Coherus Biosciences, Inc.	9662396
<b>Method of manufacturing a protein by perfusion in media with a low amino acid concentration</b>	Coherus Biosciences, Inc.	14/609225	1/29/2015	Coherus Biosciences, Inc.	10047141
<b>PPAR gamma agonists for treatment of multiple sclerosis</b>	Intekrin Therapeutics Inc.	14/707122	5/8/2015	Intekrin Therapeutics Inc.	9539249
<b>Correctly folded etanercept composition</b>	Coherus Biosciences, Inc.	14/788250	6/30/2015	Coherus Biosciences, Inc.	10975138
<b>METHODS FOR MAKING RECOMBINANT PROTEINS</b>	Coherus Biosciences, Inc.	14/845440	9/4/2015	Coherus Biosciences, Inc.	10435464
<b>Etanercept formulations stabilized with combinations of sugars and polyols</b>	Coherus Biosciences, Inc.	15/078755	3/23/2016	Coherus Biosciences, Inc.	9943601
<b>Etanercept formulations stabilized with xylitol</b>	Coherus Biosciences, Inc.	15/209484	7/13/2016	Coherus Biosciences, Inc.	9770510
<b>High concentration formulations of adalimumab</b>	Coherus Biosciences, Inc.	15/337519	10/28/2016	Coherus Biosciences, Inc.	11229702
<b>Stable protein compositions and methods of their use</b>	Coherus Biosciences, Inc.	15/337845	10/28/2016	Coherus Biosciences, Inc.	11583584
<b>PPAR<math>\gamma</math> agonists for treatment of multiple sclerosis</b>	Intekrin Therapeutics Inc.	15/402941	1/10/2017	Intekrin Therapeutics Inc.	9867816
<b>Method of filling a container with no headspace</b>	Coherus Biosciences, Inc.	15/492999	4/20/2017	Coherus Biosciences, Inc.	11071782
<b>Correctly folded etanercept in high purity and excellent yield</b>	Coherus Biosciences, Inc.	15/720291	9/29/2017	Coherus Biosciences, Inc.	11001627
<b>Syringe containing stable aqueous formulations of adalimumab</b>	Coherus Biosciences, Inc.	15/729243	10/10/2017	Coherus Biosciences, Inc.	10286071
<b>Etanercept Formulations Stabilized with Metal Ions</b>	Coherus Biosciences, Inc.	15/799798	10/31/2017	Coherus Biosciences, Inc.	11135267
<b>Method of manufacturing a protein by perfusion in media with a low amino acid concentration</b>	Coherus Biosciences, Inc.	16/102157	8/13/2018	Coherus Biosciences, Inc.	11001623
<b>ETANERCEPT FORMULATIONS</b>	Coherus Biosciences, Inc.	16/284265	2/25/2019	Coherus Biosciences, Inc.	10772963

Title	Assignee	App. No.	Filing Date	Applicant Name	Patent No.
<b>STABILIZED WITH XYLITOL</b>					
<b>Stable aqueous formulations of aflibercept</b>	Coherus Biosciences, Inc.	16/297387	3/8/2019	Coherus Biosciences, Inc.	11667702
<b>ETANERCEPT FORMULATIONS STABILIZED WITH AMINO ACIDS</b>	Coherus Biosciences, Inc.	16/360196	3/21/2019	Coherus Biosciences, Inc.	11129876
<b>Stable Aqueous Etanercept Composition</b>	Coherus Biosciences, Inc.	16/441092	6/14/2019	Coherus Biosciences, Inc.	10980884
<b>Method of Reducing Formation of Etanercept Aggregates or Fragments</b>	Coherus Biosciences, Inc.	16/441095	6/14/2019	Coherus Biosciences, Inc.	10980885
<b>Stable Aqueous Etanercept Composition</b>	Coherus Biosciences, Inc.	16/441103	6/14/2019	Coherus Biosciences, Inc.	10888619
<b>Method of Reducing Formation of Etanercept Aggregates or Fragments</b>	Coherus Biosciences, Inc.	16/441110	6/14/2019	Coherus Biosciences, Inc.	10987405
<b>Correctly folded etanercept in high purity and excellent yield</b>	Coherus Biosciences, Inc.	16/443514	6/17/2019	Coherus Biosciences, Inc.	10954293
<b>Correctly folded etanercept in high purity and excellent yield</b>	Coherus Biosciences, Inc.	16/443594	6/17/2019	Coherus Biosciences, Inc.	10954294
<b>Correctly folded etanercept in high purity and excellent yield</b>	Coherus Biosciences, Inc.	16/443688	6/17/2019	Coherus Biosciences, Inc.	10947306
<b>Correctly folded etanercept in high purity and excellent yield</b>	Coherus Biosciences, Inc.	16/443721	6/17/2019	Coherus Biosciences, Inc.	10954295
<b>Etanercept Formulations Stabilized with Sodium Chloride</b>	Coherus Biosciences, Inc.	16/456267	6/28/2019	Coherus Biosciences, Inc.	11000588
<b>PPAR<math>\gamma</math> agonist for treatment of progressive supranuclear palsy</b>	Coherus Biosciences, Inc.	16/497523	4/3/2018	Coherus Biosciences, Inc.	11253508
<b>Methods for making recombinant proteins</b>	Coherus Biosciences, Inc.	16/564642	9/9/2019	Coherus Biosciences, Inc.	11396540
<b>Stable aqueous formulations of aflibercept</b>	Coherus Biosciences, Inc.	16/566847	9/10/2019	Coherus Biosciences, Inc.	11426446
<b>Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy</b>	Coherus Biosciences, Inc.	16/744433	1/16/2020	Coherus Biosciences, Inc.	10772865
<b>Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy</b>	Coherus Biosciences, Inc.	16/911721	6/25/2020	Coherus Biosciences, Inc.	11400072
<b>Method of filling a container with no headspace</b>	Coherus Biosciences, Inc.	17/350299	6/17/2021	Coherus Biosciences, Inc.	11576971
<b>COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD)</b>	Coherus Biosciences, Inc.	17/600182	9/30/2021	Coherus Biosciences, Inc.	--
<b>Stable aqueous formulations of adalimumab</b>	Coherus Biosciences, Inc.	14/643844	3/10/2015	Coherus Biosciences, Inc.	9340611
<b>Stable aqueous formulations of adalimumab</b>	Coherus Biosciences, Inc.	14/661288	3/18/2015	Coherus Biosciences, Inc.	9340612
<b>Stable aqueous formulations of adalimumab</b>	Coherus Biosciences, Inc.	14/661849	3/18/2015	Coherus Biosciences, Inc.	9782479
<b>Stable aqueous formulations of adalimumab</b>	Coherus Biosciences, Inc.	14/661899	3/18/2015	Coherus Biosciences, Inc.	9346880
<b>Stable aqueous formulations of adalimumab</b>	Coherus Biosciences, Inc.	14/661938	3/18/2015	Coherus Biosciences, Inc.	9382317
<b>Stable aqueous formulations of adalimumab</b>	Coherus Biosciences, Inc.	14/879847	10/9/2015	Coherus Biosciences, Inc.	9724414
<b>Stable aqueous formulations of adalimumab</b>	Coherus Biosciences, Inc.	14/879885	10/9/2015	Coherus Biosciences, Inc.	9808525






Title	Assignee	App. No.	Filing Date	Applicant Name	Patent No.
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	15/155832	5/16/2016	Coherus Biosciences, Inc.	9682145
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	15/155925	5/16/2016	Coherus Biosciences, Inc.	9707293
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	15/155982	5/16/2016	Coherus Biosciences, Inc.	9789185
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	15/162140	5/23/2016	Coherus Biosciences, Inc.	9757454
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	15/193345	6/27/2016	Coherus Biosciences, Inc.	9770507
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	15/193387	6/27/2016	Coherus Biosciences, Inc.	9731008
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	15/193415	6/27/2016	Coherus Biosciences, Inc.	9737600
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	15/193454	6/27/2016	Coherus Biosciences, Inc.	9782480
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	15/193486	6/27/2016	Coherus Biosciences, Inc.	9724415
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	15/193523	6/27/2016	Coherus Biosciences, Inc.	9731009
Stable Aqueous Formulations of Adalimumab	Coherus Biosciences, Inc.	15/360678	11/23/2016	Coherus Biosciences, Inc.	9861695
Stable Aqueous Formulations of Adalimumab	Coherus Biosciences, Inc.	15/653228	7/18/2017	Coherus Biosciences, Inc.	10780163
Stable Aqueous Formulations of Adalimumab	Coherus Biosciences, Inc.	15/677857	8/15/2017	Coherus Biosciences, Inc.	10786566
Stable Aqueous Formulations of Adalimumab	Coherus Biosciences, Inc.	15/726165	10/5/2017	Coherus Biosciences, Inc.	10159732
Stable Aqueous Formulations of Adalimumab	Coherus Biosciences, Inc.	15/726195	10/5/2017	Coherus Biosciences, Inc.	10207000
Stable Aqueous Formulations of Adalimumab	Coherus Biosciences, Inc.	15/726215	10/5/2017	Coherus Biosciences, Inc.	10159733
Stable Aqueous Formulations of Adalimumab	Coherus Biosciences, Inc.	15/729295	10/10/2017	Coherus Biosciences, Inc.	10286072
Stable Aqueous Formulations of Adalimumab	Coherus Biosciences, Inc.	15/799851	10/31/2017	Coherus Biosciences, Inc.	10155039
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	15/866154	1/9/2018	Coherus Biosciences, Inc.	10195275
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	16/023046	6/29/2018	Coherus Biosciences, Inc.	10772959
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	16/023152	6/29/2018	Coherus Biosciences, Inc.	10772960
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	16/023161	6/29/2018	Coherus Biosciences, Inc.	10799585
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	16/023205	6/29/2018	Coherus Biosciences, Inc.	10688183
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	16/178137	11/1/2018	Coherus Biosciences, Inc.	10722579
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	16/178164	11/1/2018	Coherus Biosciences, Inc.	10716852
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	16/178309	11/1/2018	Coherus Biosciences, Inc.	10716853
Stable aqueous formulations of adalimumab	Coherus Biosciences, Inc.	16/178319	11/1/2018	Coherus Biosciences, Inc.	10716854
ANTI-IL-27 ANTIBODIES AND USES THEREOF	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	17/738927	5/6/2022	Surface Oncology, Inc.	--
ANTI-IL-27 ANTIBODIES AND USES THEREOF	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	17/413269	06/11/2021	Surface Oncology, Inc.	--

Title	Assignee	App. No.	Filing Date	Applicant Name	Patent No.
<b>Anti-IL-27 antibodies and uses thereof</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	16/362457	3/22/2019	Surface Oncology, Inc.	11332524
<b>ANTI-IL-27 ANTIBODIES AND USES THEREOF</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	17/714942	4/6/2022	Surface Oncology, Inc.	--
<b>Antibody molecules to CD73 and uses thereof</b>	Novartis AG; Surface Oncology, LLC (formerly Surface Oncology, Inc.)	16/014744	6/21/2018	Novartis AG; Surface Oncology, Inc.	11312783
<b>Anti-CD39 Antibody Compositions and Methods</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	17/021223	9/15/2020	Surface Oncology, Inc.	11655303
<b>Antibodies that bind CD39 and uses thereof</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	16/352589	3/13/2019	Surface Oncology, Inc.	10738128
<b>Antibodies that bind CD39 and uses thereof</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	15/931469	5/13/2020	Surface Oncology, Inc.	10793637
<b>Anti-CD112R Compositions and Methods</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	16/516613	7/19/2019	Surface Oncology, Inc.	11279758
<b>COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD)</b>	Coherus Biosciences, Inc.	17768538	4/13/2022	Coherus Biosciences, Inc.	--
<b>CONTROL MECHANISM FOR PRIMING AN INJECTION DEVICE</b>	Coherus Biosciences, Inc.	17765294	5/30/2022	Coherus Biosciences, Inc.	--
<b>COMPOSITIONS AND METHODS TO TREAT CANCER</b>	Coherus Biosciences, Inc.	17613012	11/19/2021	Coherus Biosciences, Inc.	--
<b>COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD)</b>	Coherus Biosciences, Inc.	17/600194	9/30/2021	Coherus Biosciences, Inc.	--
<b>COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD)</b>	Coherus Biosciences, Inc.	17/600178	9/30/2021	Coherus Biosciences, Inc.	--
<b>COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD)</b>	Coherus Biosciences, Inc.	17/600172	9/30/2021	Coherus Biosciences, Inc.	--
<b>COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD)</b>	Coherus Biosciences, Inc.	17600168	9/30/2021	Coherus Biosciences, Inc.	--
<b>COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD)</b>	Coherus Biosciences, Inc.	17419559	6/29/2021	Coherus Biosciences, Inc.	--
<b>Anti-CD112R Compositions and Methods</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	17261463	1/19/2021	Surface Oncology, Inc.	11214619
<b>ANTIBODY MOLECULES TO CD73 AND USES THEREOF</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.), Adimab, LLC, Novartis AG	17/059056	11/25/2020	Surface Oncology, Inc., Adimab, LLC, Novartis AG	--
<b>Anti-CD112R Compositions and Methods</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	17/531380	11/19/2021	Surface Oncology, Inc.	--
<b>ANTIBODY MOLECULES TO CD73 AND USES THEREOF</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.); Novartis AG	17/695267	3/15/2022	Surface Oncology, Inc.; Novartis AG	--

Title	Assignee	App. No.	Filing Date	Applicant Name	Patent No.
<b>METHODS OF TREATING CANCER WITH AN ANTI-CD39 ANTIBODY AND PEMBROLIZUMAB</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.); MSD International GmbH	17/830817	6/2/2022	Surface Oncology, Inc.; MSD International GmbH	--
<b>USE OF ANTI-IL-27 ANTIBODIES</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.); F. Hoffman-La Roche AG	18/201626	5/24/2023	Surface Oncology, Inc.; F. Hoffman-La Roche AG	--
<b>USE OF ANTI-IL-27 ANTIBODIES</b>	Surface Oncology, LLC (formerly Surface Oncology, Inc.); MSD International GmbH	18/201620	5/24/2023	Surface Oncology, Inc.; MSD International GmbH	--

2. Trademarks:

Trademark	Owner	Application Number Application Date	Registration Number Registration Date	Status
YUSIMRY	Coherus Biosciences, Inc.	90169471 09/09/2020	7243078 12/12/2023	Registered
UDENYCA	Coherus Biosciences, Inc.	86731671 08/20/2015	5710007 03/26/2019	Registered
LOQTORZ	Coherus Biosciences, Inc.	90642116 04/13/2021	7327960 03/12/2024	Registered
COHERUS	Coherus Biosciences, Inc.	90858291 07/30/2021	6921362 12/13/2022	Registered
	Coherus Biosciences, Inc.	86731667 08/20/2015	6147626 09/08/2020	Registered
COHERUS BIOSCIENCES	Coherus Biosciences, Inc.	90858305 07/30/2021	6921363 12/13/2022	Registered
COHERUS	Coherus Biosciences, Inc.	98344332 01/05/2024	--	Pending
	Coherus Biosciences, Inc.	98344323 01/05/2024	--	Pending
SURFACE ONCOLOGY	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	88720992 12/10/2019	7183187 10/03/2023	Registered
	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	87712553 12/07/2017	5710905 03/26/2019	Registered
SURFACE ONCOLOGY	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	88772026 01/24/2020	7183207 10/03/2023	Registered
SURFACE ONCOLOGY	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	87710745 12/06/2017	5874928 10/01/2019	Registered
SURFACE ONCOLOGY	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	88714928 12/04/2019	6094924 07/07/2020	Registered
SURFACE ONCOLOGY	Surface Oncology, LLC (formerly Surface Oncology, Inc.)	88714919 12/04/2019	6094923 07/07/2020	Registered

### 3. *IP LICENSES*

- 1) Settlement and License Agreement between AbbVie Inc. and the Borrower (YUSIMRY).
- 2) Exclusive License and Commercialization Agreement between the Borrower and Shanghai Junshi Biosciences Co., Ltd., as amended by Amendment to and Waiver under Exclusive License and Commercialization Agreement dated as of October 27, 2023 and Amendment No. 2 to Exclusive License and Commercialization Agreement, dated as of March 13, 2024.
- 3) Framework Agreement between the Borrower and Sorrel Medical Ltd. (UDENYCA OBI).
- 4) License between Amgen Inc. and Intekrin (CHS-131).
- 5) Exclusive License Agreement between ProBioGen AG and the Borrower (YUSIMRY).
- 6) Settlement and License Agreement dated October 2019 between Pfizer Inc. and the Borrower.
- 7) Amended and Restated Development and Option Agreement dated October 2018 between Surface Oncology, Inc. and Adimab LLC (as amended).
- 8) Exclusive Product License Agreement dated March 23, 2021 between Surface Oncology, Inc. and Vaccinex, Inc.
- 9) Non-Exclusive License Agreement, dated as of February 24, 2023, by and between Borrower and the Dana-Farber Cancer Institute, Inc.
- 10) Letter Agreement, dated January 9, 2022, by and between the Seller and Shanghai Junshi Biosciences Co., Ltd.

#### **Out-Licenses**

- 1) Clinical Collaboration and Supply Agreement between Inovio and Borrower dated December 21, 2023.
- 2) Letter Agreement, dated January 9, 2022, by and between the Seller and Shanghai Junshi Biosciences Co., Ltd.
- 3) Clinical Collaboration and Supply Agreement among Cancer Research Institution, ENB Therapeutics, Inc. and Borrower, dated as of May 6, 2024.
- 4) Distribution Agreement between Gador and Borrower Trademark License Agreement between Borrower and Junshi Biosciences dated January 31, 2024.